ATE511502T1 - Arylpropionamid-, arylacrylamid-, arylpropinamid- oder arylmethylharnstoffanaloge als faktor-xia- inhibitoren - Google Patents

Arylpropionamid-, arylacrylamid-, arylpropinamid- oder arylmethylharnstoffanaloge als faktor-xia- inhibitoren

Info

Publication number
ATE511502T1
ATE511502T1 AT06846594T AT06846594T ATE511502T1 AT E511502 T1 ATE511502 T1 AT E511502T1 AT 06846594 T AT06846594 T AT 06846594T AT 06846594 T AT06846594 T AT 06846594T AT E511502 T1 ATE511502 T1 AT E511502T1
Authority
AT
Austria
Prior art keywords
arylpropinamide
arylmethylurea
arylpropionamide
arylacrylamide
analogues
Prior art date
Application number
AT06846594T
Other languages
English (en)
Inventor
Donald Pinto
Joanne Smallheer
James R Corte
Zilun Hu
Cullen L Cavallaro
Paul Gilligan
Mimi L Quan
Leon Ii Smith
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Application granted granted Critical
Publication of ATE511502T1 publication Critical patent/ATE511502T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/68—Halogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/18—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
AT06846594T 2005-12-14 2006-12-13 Arylpropionamid-, arylacrylamid-, arylpropinamid- oder arylmethylharnstoffanaloge als faktor-xia- inhibitoren ATE511502T1 (de)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US75013005P 2005-12-14 2005-12-14
US82116306P 2006-08-02 2006-08-02
US86521106P 2006-11-10 2006-11-10
PCT/US2006/062005 WO2007070826A1 (en) 2005-12-14 2006-12-13 Arylpropionamide, arylacrylamide, arylpropynamide, or arylmethylurea analogs as factor xia inhibitors

Publications (1)

Publication Number Publication Date
ATE511502T1 true ATE511502T1 (de) 2011-06-15

Family

ID=37944011

Family Applications (1)

Application Number Title Priority Date Filing Date
AT06846594T ATE511502T1 (de) 2005-12-14 2006-12-13 Arylpropionamid-, arylacrylamid-, arylpropinamid- oder arylmethylharnstoffanaloge als faktor-xia- inhibitoren

Country Status (16)

Country Link
US (4) US7626039B2 (de)
EP (1) EP1981854B1 (de)
JP (1) JP5225098B2 (de)
KR (1) KR20080087817A (de)
AR (1) AR058379A1 (de)
AT (1) ATE511502T1 (de)
AU (1) AU2006325754B2 (de)
BR (1) BRPI0620010A2 (de)
CA (1) CA2633252A1 (de)
EA (1) EA014245B1 (de)
IL (1) IL192033A0 (de)
NO (1) NO20082444L (de)
NZ (1) NZ568595A (de)
PE (1) PE20070811A1 (de)
TW (1) TW200730477A (de)
WO (1) WO2007070826A1 (de)

Families Citing this family (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7453002B2 (en) 2004-06-15 2008-11-18 Bristol-Myers Squibb Company Five-membered heterocycles useful as serine protease inhibitors
WO2006076575A2 (en) * 2005-01-13 2006-07-20 Bristol-Myers Squibb Company Substituted biaryl compounds as factor xia inhibitors
CN101341124A (zh) * 2005-12-14 2009-01-07 布里斯托尔-迈尔斯斯奎布公司 可用作丝氨酸蛋白酶抑制剂的6元杂环
WO2007070816A2 (en) * 2005-12-14 2007-06-21 Bristol-Myers Squibb Company Thiophene derivatives as factor xia inhibitors
EP2102189B1 (de) * 2006-12-15 2015-07-29 Bristol-Myers Squibb Company Arylpropionamid-, arylacrylamid-, arylpropynamid- bzw. arylmethylharnstoff- analoga als faktor-xia-hemmer
MX2009012847A (es) * 2007-06-13 2009-12-08 Bristol Myers Squibb Co Analogos dipeptidicos como inhibidores de factores de coagulacion.
JP5537442B2 (ja) * 2008-03-13 2014-07-02 ブリストル−マイヤーズ スクイブ カンパニー 第ｘｉａ因子阻害剤としてのピリダジン誘導体
MX2011011025A (es) * 2009-04-20 2011-11-02 Osi Pharmaceuticals Llc Preparacion de c-piracin-metilaminas.
MX2012003560A (es) * 2009-09-25 2012-10-05 Astellas Pharma Inc Compuesto de amida sustituida.
EP2534154B1 (de) 2010-02-11 2020-08-05 Bristol-Myers Squibb Company Makrocyclen als faktor-xia-inhibitoren
LV14606B (lv) 2011-05-17 2013-01-20 Tetra, Sia Jauns XII faktora inhibitors
AU2012278976B2 (en) * 2011-07-06 2017-05-11 Gilead Sciences, Inc. Compounds for the treatment of HIV
TW201311689A (zh) 2011-08-05 2013-03-16 必治妥美雅史谷比公司 作為因子ｘｉａ抑制劑之新穎巨環化合物
TW201319068A (zh) 2011-08-05 2013-05-16 必治妥美雅史谷比公司 作為ｘｉａ因子抑制劑之環狀ｐ１接合劑
CN103987696B (zh) 2011-10-14 2016-12-21 百时美施贵宝公司 作为因子xia抑制剂的取代的四氢异喹啉化合物
WO2013055984A1 (en) 2011-10-14 2013-04-18 Bristol-Myers Squibb Company Substituted tetrahydroisoquinoline compounds as factor xia inhibitors
PH12014500625B1 (en) 2011-10-14 2018-12-12 Bristol Myers Squibb Co Substituted tetrahydroisoquinoline compounds as factor xia inhibitors
GB2497806A (en) * 2011-12-21 2013-06-26 Ono Pharmaceutical Co Pyridinone and pyrimidinone derivatives as factor XIa inhibitors
DK2794597T3 (en) 2011-12-21 2018-01-15 Ono Pharmaceutical Co PYRIDINON AND PYRIMIDINON DERIVATIVES AS FACTOR XIA INHIBITORS
US8889730B2 (en) 2012-04-10 2014-11-18 Pfizer Inc. Indole and indazole compounds that activate AMPK
GB201209138D0 (en) 2012-05-24 2012-07-04 Ono Pharmaceutical Co Compounds
GB201212081D0 (en) * 2012-07-06 2012-08-22 Kalvista Pharmaceuticals Ltd New polymorph
SMT201700240T1 (it) 2012-08-03 2017-07-18 Bristol Myers Squibb Co Diidropiridone-p1 come inibitore del fattore xia
PL2882734T3 (pl) 2012-08-03 2017-05-31 Bristol-Myers Squibb Company Dihydropirydon jako inhibitory czynnika XIA
TR201807316T4 (tr) 2012-10-12 2018-06-21 Bristol Myers Squibb Co Bir faktör XIa inhibitörünün kristalli formları.
EP2906552B1 (de) 2012-10-12 2017-11-22 Bristol-Myers Squibb Company Guanidinsubstituierte tetrahydroisochinoline als factor xia inhibitoren
EP2906541B1 (de) 2012-10-12 2017-11-22 Bristol-Myers Squibb Company Guanidin- und aminsubstituierte tetrahydroisochinoline als factor xia inhibitoren
GB201300304D0 (en) * 2013-01-08 2013-02-20 Kalvista Pharmaceuticals Ltd Benzylamine derivatives
JP6064062B2 (ja) 2013-03-15 2017-01-18 ファイザー・インク Ａｍｐｋを活性化させるインダゾール化合物
ES2712699T3 (es) 2013-03-25 2019-05-14 Bristol Myers Squibb Co Tetrahidroisoquinolinas que contienen azoles sustituidos como inhibidores del factor XIa
EA201300843A1 (ru) * 2013-08-01 2015-04-30 Арсений Валерьевич Айбушев Карбамоилфенильные производные для остановки, предотвращения и профилактики кровотечений или усиления системы гемостаза
GB2517908A (en) * 2013-08-14 2015-03-11 Kalvista Pharmaceuticals Ltd Bicyclic inhibitors
WO2015054087A1 (en) 2013-10-07 2015-04-16 Merck Sharp & Dohme Corp. FACTOR XIa INHIBITORS
SI3099687T1 (en) 2014-01-31 2018-08-31 Bristol-Myers Squibb Company Macrocycles with hetrocyclic p2' groups as factor xia inhibitors
NO2760821T3 (de) 2014-01-31 2018-03-10
EP3104703B1 (de) 2014-02-11 2020-11-18 Merck Sharp & Dohme Corp. Faktor-xia-hemmer
US9676723B2 (en) * 2014-02-11 2017-06-13 Merck Sharp & Dohme Corp Factor XIa inhibitors
KR20160118368A (ko) * 2014-02-25 2016-10-11 아칠리온 파르마세우티칼스 인코포레이티드 보체 매개된 장애의 치료를 위한 에터 화합물
WO2015160636A1 (en) 2014-04-16 2015-10-22 Merck Sharp & Dohme Corp. Factor ixa inhibitors
WO2015164308A1 (en) 2014-04-22 2015-10-29 Merck Sharp & Dohme Corp. FACTOR XIa INHIBITORS
EA201790185A1 (ru) 2014-07-15 2017-07-31 Грюненталь Гмбх Замещенные азаспиро(4.5)декановые производные
TW201607923A (zh) 2014-07-15 2016-03-01 歌林達有限公司 被取代之氮螺環（４．５）癸烷衍生物
US9868727B2 (en) 2014-07-28 2018-01-16 Merck Sharp & Dohme Corp. Factor XIa inhibitors
EP3177642B1 (de) 2014-08-07 2021-11-24 Novartis AG Angiopoietin-like-4-antikörper und verfahren zur verwendung
TW201613977A (en) 2014-08-07 2016-04-16 Novartis Ag Angiopoetin-like 4 (ANGPTL4) antibodies and methods of use
EP3189047B1 (de) 2014-09-04 2018-12-26 Bristol-Myers Squibb Company Diamidmakrocyclen als fxia-inhibitoren
US9453018B2 (en) 2014-10-01 2016-09-27 Bristol-Myers Squibb Company Pyrimidinones as factor XIa inhibitors
EP3229801B1 (de) 2014-12-10 2020-04-01 Merck Sharp & Dohme Corp. Faktor-ixa-hemmer
SG11201704708QA (en) 2014-12-10 2017-07-28 Ono Pharmaceutical Co Dihydroindolizinone derivative
EP3302060B1 (de) * 2015-05-26 2020-02-12 Kaohsiung Medical University Pyrazolo[4,3-c]chinolin-derivate zur hemmung von beta-glucuronidase
EP3310777B1 (de) 2015-06-19 2019-10-09 Bristol-Myers Squibb Company Diamid makrocyclen als faktor xia inhibitoren
JOP20200312A1 (ar) 2015-06-26 2017-06-16 Novartis Ag الأجسام المضادة للعامل xi وطرق الاستخدام
CN107922393A (zh) 2015-07-29 2018-04-17 百时美施贵宝公司 携带非芳族p2,基团的因子xia新大环
EP3328851B1 (de) 2015-07-29 2020-04-22 Bristol-Myers Squibb Company Makrocyclische inhibitoren von xia-faktor mit alkyl- oder cycloalkyl-p2'-gruppen
MX387515B (es) 2015-10-29 2025-03-18 Merck Sharp & Dohme Llc Inhibidores de factor xia.
WO2017074833A1 (en) 2015-10-29 2017-05-04 Merck Sharp & Dohme Corp. Macrocyclic spirocarbamate derivatives as factor xia inhibitors, pharmaceutically acceptable compositions and their use
US10472344B2 (en) 2015-12-02 2019-11-12 Merck Sharp & Dohme Corp. Factor XIa inhibitors
WO2017123518A1 (en) * 2016-01-11 2017-07-20 The Rockefeller University Aminotriazole immunomodulators for treating autoimmune diseases
TW201802121A (zh) 2016-05-25 2018-01-16 諾華公司 抗因子XI/XIa抗體之逆轉結合劑及其用途
TWI853404B (zh) 2016-08-19 2024-08-21 美商基利科學股份有限公司 治療性化合物
EP3500556B1 (de) 2016-08-22 2023-08-02 Merck Sharp & Dohme LLC Pyridine-1-oxid derivate und deren verwendung als factor xia inhibitoren
CN110325550B (zh) 2016-12-23 2024-03-08 诺华股份有限公司 因子xi抗体和使用方法
TW202024061A (zh) 2017-08-17 2020-07-01 美商基利科學股份有限公司 Hiv蛋白質膜抑制劑之固體形式
AR112412A1 (es) 2017-08-17 2019-10-23 Gilead Sciences Inc Formas de sal de colina de un inhibidor de la cápside del vih
AU2019221568B2 (en) 2018-02-15 2021-04-22 Gilead Sciences, Inc. Pyridine derivatives and their use for treating HIV infection
TWI823164B (zh) 2018-02-16 2023-11-21 美商基利科學股份有限公司 用於製備有療效化合物之方法及中間物
TWI814350B (zh) 2018-07-16 2023-09-01 美商基利科學股份有限公司 用於治療hiv之蛋白殼抑制劑
EP4065116B1 (de) 2019-11-26 2026-01-21 Gilead Sciences, Inc. Capsid-inhibitoren zur vorbeugung von hiv
TWI858267B (zh) 2020-06-25 2024-10-11 美商基利科學股份有限公司 用於治療hiv之蛋白殼抑制劑
EP4247372A4 (de) * 2020-11-19 2024-11-06 Merck Sharp & Dohme LLC Plasmakallikreinhemmer
AU2022403012B2 (en) 2021-12-03 2026-02-12 Gilead Sciences, Inc. Therapeutic compounds for hiv virus infection
CA3237155A1 (en) 2021-12-03 2023-06-08 Zhimin Du Therapeutic compounds for hiv virus infection
SI4440702T1 (sl) 2021-12-03 2025-09-30 Gilead Sciences, Inc. Terapevtske spojine za okužbo z virusom hiv

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998027108A2 (en) 1996-12-16 1998-06-25 Fujisawa Pharmaceutical Co., Ltd. New amide compounds and their use as nitric oxide synthase inhibitors
US6593291B1 (en) 1997-02-06 2003-07-15 Entremed, Inc. Compositions and methods of use of ligands that bind components of the blood coagulation/clotting pathway for the treatment of cancer and angiogenic-based disease
ZA985247B (en) * 1997-06-19 1999-12-17 Du Pont Merck Pharma Guanidine mimics as factor Xa inhibitors.
JP2003523921A (ja) * 1998-06-12 2003-08-12 ソシエテ・ドゥ・コンセイユ・ドゥ・ルシェルシュ・エ・ダプリカーション・シャンティフィック・エス・ア・エス イミダゾリル誘導体
RU2242481C2 (ru) * 1998-06-16 2004-12-20 Сосьете Де Консей Де Решерш Э Д'Аппликасьон Сьентифик Сас Аналоги циклического соматостатина
AUPQ142599A0 (en) * 1999-07-05 1999-07-29 Fujisawa Pharmaceutical Co., Ltd. New amide compounds
US20040132788A1 (en) 1999-10-11 2004-07-08 Chabrier De Lassauniere Pierre-Etienne Derivatives of heterocycles with 5 members, their preparation and their use as medicaments
AR035040A1 (es) 2000-08-01 2004-04-14 Sod Conseils Rech Applic Derivados de imidazolilo, composiciones farmaceuticas que los comprenden y el uso de los mismos para la preparacion de medicamentos capaces de unir selectivamente a los subtipos del receptor de somatostatina
CA2473169A1 (en) * 2002-01-31 2003-08-07 Morphochem Aktiengesellschaft Fuer Kombinatorische Chemie Compounds that inhibit factor xa activity
US20040186151A1 (en) * 2003-02-12 2004-09-23 Mjalli Adnan M.M. Substituted azole derivatives as therapeutic agents
US20040180855A1 (en) * 2003-02-19 2004-09-16 Schumacher William A. Methods of treating thrombosis with reduced risk of increased bleeding times
US7138412B2 (en) * 2003-03-11 2006-11-21 Bristol-Myers Squibb Company Tetrahydroquinoline derivatives useful as serine protease inhibitors
US7129264B2 (en) * 2003-04-16 2006-10-31 Bristol-Myers Squibb Company Biarylmethyl indolines and indoles as antithromboembolic agents
US7371743B2 (en) * 2004-02-28 2008-05-13 Boehringer Ingelheim International Gmbh Carboxylic acid amides, the preparation thereof and their use as medicaments
CN1950342B (zh) * 2004-03-15 2012-09-26 詹森药业有限公司 作为阿片受体调节剂的新化合物
US7417063B2 (en) * 2004-04-13 2008-08-26 Bristol-Myers Squibb Company Bicyclic heterocycles useful as serine protease inhibitors
WO2005115990A1 (ja) * 2004-05-26 2005-12-08 Eisai R & D Management Co., Ltd. シンナミド化合物
US7429604B2 (en) * 2004-06-15 2008-09-30 Bristol Myers Squibb Company Six-membered heterocycles useful as serine protease inhibitors
US7453002B2 (en) * 2004-06-15 2008-11-18 Bristol-Myers Squibb Company Five-membered heterocycles useful as serine protease inhibitors
JP5197014B2 (ja) 2004-12-10 2013-05-15 イステイチユート・デイ・リチエルケ・デイ・ビオロジア・モレコラーレ・ピ・アンジエレツテイ・エツセ・エルレ・エルレ ヒストンデアセチラーゼ（ｈｄａｃ）阻害剤としての複素環誘導体
WO2006076575A2 (en) * 2005-01-13 2006-07-20 Bristol-Myers Squibb Company Substituted biaryl compounds as factor xia inhibitors
WO2007070816A2 (en) 2005-12-14 2007-06-21 Bristol-Myers Squibb Company Thiophene derivatives as factor xia inhibitors
CN101341124A (zh) 2005-12-14 2009-01-07 布里斯托尔-迈尔斯斯奎布公司 可用作丝氨酸蛋白酶抑制剂的6元杂环

Also Published As

Publication number Publication date
US7626039B2 (en) 2009-12-01
AU2006325754B2 (en) 2012-04-12
NO20082444L (no) 2008-09-12
TW200730477A (en) 2007-08-16
CA2633252A1 (en) 2007-06-21
NZ568595A (en) 2010-04-30
JP5225098B2 (ja) 2013-07-03
AU2006325754A1 (en) 2007-06-21
EP1981854B1 (de) 2011-06-01
WO2007070826A1 (en) 2007-06-21
US20120270853A1 (en) 2012-10-25
US8604056B2 (en) 2013-12-10
US20110028446A1 (en) 2011-02-03
IL192033A0 (en) 2008-12-29
PE20070811A1 (es) 2007-08-13
KR20080087817A (ko) 2008-10-01
US20100022506A1 (en) 2010-01-28
US20080161373A1 (en) 2008-07-03
JP2009519967A (ja) 2009-05-21
AR058379A1 (es) 2008-01-30
EA014245B1 (ru) 2010-10-29
EA200801530A1 (ru) 2008-12-30
WO2007070826B1 (en) 2007-08-16
BRPI0620010A2 (pt) 2011-11-22
US8252830B2 (en) 2012-08-28
EP1981854A1 (de) 2008-10-22
US7842708B2 (en) 2010-11-30

Similar Documents

Publication Publication Date Title
ATE511502T1 (de) Arylpropionamid-, arylacrylamid-, arylpropinamid- oder arylmethylharnstoffanaloge als faktor-xia- inhibitoren
NL300935I2 (nl) guselkumab.
DK1928882T3 (da) (s)-n-methylnaltrexon
ATE490254T1 (de) Imidazoä1,2-aüpyridin-verbindungen als vegf-r2- hemmer
DK1979356T3 (da) Carbonylaminopyrrolopyrazoler, kraftige kinaseinhibitorer
EP1775630A4 (de) Tasche
DE602005011440D1 (de) Höhenmessuhr
DE602006016566D1 (de) Als antikoagulanzien verwendbare phenylglycinamid-derivate
NO20051199L (no) Rorhandteringsutstyr.
DK1943406T3 (da) Byggeelement
EP1916896A4 (de) Nichtsteroid-antiandrogene
DE502006005768D1 (de) Hydrolysestabilisatorformulierungen
DE602005009179D1 (de) Telekommunikatiosverbinder
NO20053362L (no) Syklofuge.
DE502006005182D1 (de) Heterocyclylamid-substituierte imidazole
DE602005023501D1 (de) Radhausbau
DE502006005207D1 (de) Bauteilen
DE602005021060D1 (de) Notrufleitweglenkung
DE502006001397D1 (de) Lagerbuchse
ITMI20050051A1 (it) Fotodiodio organico di poli-9,9-diottil-fluorene
FI20050681A0 (fi) Paikoitusmenetelmä
DE502006000445D1 (de) Mulchmähdeck
DE502006004709D1 (de) Gurtstraffvorrichtung
EP1915490A4 (de) Duchführungsanordnung
DE502006004162D1 (de) Fahrzeugtemperiersystem

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties